Arcus Biosciences, Inc. Ratios | P/E, ROE & Valuation

On the Key Ratios page for Arcus Biosciences, Inc. (RCUS), the latest P/E of -4.3 frames valuation, while ROE -90.04% and ROIC -75.04% indicates profitability and capital efficiency. Together with the current ratio of 3.34 and debt-to-equity 0.32, these signals help you judge whether valuation is supported by fundamentals across the historical rows.

Financial Performance Ratios

RCUS Historical Per Share Metrics

10 years
Metric (FY)TTM202420232022202120202019201820172016
Revenue per Share$0.78$2.86$1.58$1.56$5.52$1.42$0.34$0.24$0.06$0.00
Net Income per Share$-3.49$-3.14$-4.15$-3.71$0.76$-2.25$-1.93$-1.43$-2.16$-0.73
Operating Cash Flow per Share$-3.65$-1.89$-4.14$6.08$-3.69$2.03$-1.68$-1.24$-1.02$-0.53
Free Cash Flow per Share$-3.66$-1.95$-4.46$5.92$-4.07$1.97$-1.72$-1.35$-1.25$-0.69
Cash per Share$4.95$10.85$10.26$14.01$7.20$13.30$4.30$7.41$7.16$4.03
Book Value per Share$2.81$5.38$6.24$9.12$12.13$9.17$3.74$6.79$6.27$4.05
Tangible Book Value per Share$2.81$5.38$6.24$9.12$12.13$9.17$3.74$6.79$6.27$4.05
Interest Debt per Share$1.09$0.71$0.18$1.69$1.69$0.28$0.00$0.00$0.00$0.00
CAPEX per Share$0.01$0.07$0.32$0.17$0.38$0.06$0.04$0.11$0.22$0.17

RCUS Historical Valuation Ratios

10 years
Metric (FY)TTM202420232022202120202019201820172016
Price to Earnings (P/E)-4.27-4.74-4.6-5.5852.95-11.56-5.23-7.52-7.86-23.23
Price to Book (P/B)5.562.773.062.273.342.832.71.592.714.2
Price to Sales (P/S)22.495.212.0813.297.3318.2329.5144.64295.420
Enterprise Value to EBITDA-5.37-4.65-4.46-5.4447.04-10.53-4.74-5.89-6.28-20.88
EV to Sales22.144.8511.0912.537.2516.2125.6536.13225.760
EV to Operating Cash Flow-4.76-7.36-4.243.2-10.8311.37-5.24-7.02-12.73-27.21
EV to Free Cash Flow-4.75-7.11-3.933.29-9.8311.69-5.1-6.46-10.43-20.67
Enterprise Value$2.21B$1.25B$1.30B$1.40B$2.78B$1.26B$384.71M$301.77M$319.00M$352.27M

RCUS Historical Profitability Ratios

10 years
Metric (FY)TTM202420232022202120202019201820172016
Return on Equity (ROE)-90.04%-58.35%-66.45%-40.64%6.30%-24.49%-51.70%-21.11%-34.50%-18.07%
Return on Invested Capital (ROIC)-75.04%-35.38%-37.61%-24.33%3.65%-19.06%-49.17%-21.26%-30.06%-17.46%
Return on Tangible Assets-54.40%-24.61%-28.04%-19.85%3.33%-15.93%-41.71%-18.04%-27.87%-16.38%
Earnings Yield-22.36%-21.09%-21.72%-17.93%1.89%-8.65%-19.14%-13.30%-12.72%-4.30%
Free Cash Flow Yield-20.72%-13.12%-23.35%28.61%-10.06%7.60%-17.03%-12.54%-7.32%-4.08%
Dividend Yield0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

RCUS Historical Liquidity & Financial Strength

10 years
Metric (FY)TTM202420232022202120202019201820172016
Current Ratio3.344.54.525.534.16.048.4915.2913.917.98
Interest Coverage-20.65-82.5-170-140000000
Income Quality1.030.61-1.64-4.85-0.90.870.870.470.72
Debt to Equity0.320.120.020.180.140.030000
Debt to Assets14.18%5.22%1.00%8.92%7.34%1.97%0.00%0.00%0.00%0.00%
Net Debt to EBITDA0.080.330.40.33-0.531.320.711.391.943.86

RCUS Historical Efficiency Ratios

10 years
Metric (FY)TTM202420232022202120202019201820172016
Receivables Turnover5.5610.322.792.60.5145.94113.64100.6456.520
Payables Turnover0.110.5600000000.34
Inventory Turnover0000000000
Days Sales Outstanding65.735.37131.03140.13709.997.953.213.636.460
Days Payables Outstanding321265700000001074.17
Days of Inventory on Hand0000000000

RCUS Historical Market Metrics

10 years
Metric (FY)TTM202420232022202120202019201820172016
Enterprise Value to EBITDA-5.37-4.65-4.46-5.4447.04-10.53-4.74-5.89-6.28-20.88
Market Cap$2.25B$1.34B$1.41B$1.49B$2.81B$1.42B$442.64M$372.84M$417.43M$417.43M
Enterprise Value$2.21B$1.25B$1.30B$1.40B$2.78B$1.26B$384.71M$301.77M$319.00M$352.27M
Dividend Yield0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Payout Ratio0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Frequently Asked Questions

How does Arcus Biosciences, Inc.’s P/E ratio compare with its history?

On this page, RCUS's current P/E is -4.3, compared with a multi-year average around 53.0. A lower P/E versus its own history is a calculated gap versus that average—not a conclusion that the stock is cheap. Pair it with profitability and earnings quality in the table (for example ROE/ROIC) to see whether the multiple moved with earnings.

What is Arcus Biosciences, Inc. market cap?

Market cap is the market value of a company's equity and is commonly calculated as share price multiplied by shares outstanding. The latest market cap shown in the table is $2.25B. Pair market cap with valuation multiples (P/E, P/B, P/S) so you can evaluate whether size also corresponds with "quality" and profitability. For a wider view across stocks, you can also use the stock screener.

How does Arcus Biosciences, Inc.’s P/E compare with its industry?

There is no P/E Tickerplace rates as good. Compare the P/E on this page with Arcus Biosciences, Inc.'s own historical range (in the table) and with peers via the Screener and Compare tools. A higher or lower multiple versus peers is a calculated gap, not a recommendation.

How does Arcus Biosciences, Inc. compare to its competitors in key financial ratios?

The fastest way to compare Arcus Biosciences, Inc. with competitors is to use the built-in "Peers Comparison" section on this page and the Compare tool. Focus on a small set of ratios that work together: P/E for valuation, ROE/ROIC for profitability and capital efficiency, current ratio and interest coverage for liquidity and solvency, and debt-to-equity for leverage risk. When you see Arcus Biosciences, Inc. outperform peers on profitability while keeping valuation and leverage reasonable, it often signals stronger fundamentals.

What do Arcus Biosciences, Inc.'s liquidity and leverage ratios show?

Liquidity and leverage figures on this page are published ratios, not a verdict that Arcus Biosciences, Inc. is financially strong. Current ratio is about 3.34, which is above 1.0 and can indicate more comfortable short-term liquidity. Interest coverage is about -20.65, implying less buffer for servicing interest costs. Debt-to-equity is about 0.32, suggesting leverage is more moderate relative to a high-debt profile. Pair them with ROE/ROIC and cash-flow rows in the table. Tickerplace does not rate the company as a good or poor investment.

What do Arcus Biosciences, Inc.'s financial ratios say about its future growth?

Ratios are a way to see what the business is likely to sustain. Look for upward trends in profitability metrics (ROE and ROIC), improving earnings/cash-flow backed measures, and stable or strengthening liquidity. If Arcus Biosciences, Inc. is sustaining strong returns (for example ROE at -90.04% and ROIC at -75.04%) while debt levels and interest coverage remain manageable, growth expectations may be more credible. If valuation multiples expand while returns weaken, the market may be pricing optimistic growth ahead of results.